Conceptualizing the relationship between chronic migraine and episodic migraine

References

• Headache Classification Committee. New appendix criteria open for a broader concept of chronic migraine. Cephalalgia26, 742–746 (2006).
   PubMed Web of Science ®Google Scholar
• Robins E, Guze SB. Establishment of diagnostic validity in psychiatric illness: its application to schizophrenia. Am. J. Psychiatry126, 983–987 (1970).
   PubMed Web of Science ®Google Scholar
• Haut SR, Bigal ME, Lipton RB. Chronic disorders with episodic manifestations: focus on epilepsy and migraine. Lancet Neurol.5, 148–157 (2006).
   PubMed Web of Science ®Google Scholar
• Boardman HF, Thomas E, Millson DS, Croft PR. The natural history of headache: predictors of onset and recovery. Cephalalgia26, 1080–1088 (2006).
   PubMedGoogle Scholar
• Bille B. A 40-year follow-up of school children with migraine. Cephalalgia17, 488–491 (1997).
   PubMed Web of Science ®Google Scholar
• Bigal ME, Lipton RB. When migraine progresses: transformed or chronic migraine. Expert Rev. Neurother.6, 297–306 (2006).
   PubMedGoogle Scholar
• D’Amico D, Grazzi L, Usai S, Rigamonti A, Curone M, Bussone G. Disability pattern in chronic migraine with medication overuse: a comparison with migraine without aura. Headache45, 553–560 (2005).
   PubMed Web of Science ®Google Scholar
• Bigal ME, Rapoport AM, Lipton RB, Tepper SJ, Sheftell FD. Assessment of migraine disability using the migraine disability assessment (MIDAS) questionnaire: a comparison of chronic migraine with episodic migraine. Headache43, 336–342 (2003).
   PubMed Web of Science ®Google Scholar
• Scher AI, Stewart WF, Ricci JA, Lipton RB. Factors associated with the onset and remission of chronic daily headache in a population-based study. Pain106, 81–89 (2003).
   PubMed Web of Science ®Google Scholar
• Lipton RB, Bigal ME. Migraine: epidemiology, impact, and risk factors for progression. Headache45(Suppl. 1), S3–S13 (2005).
   Google Scholar
• Bigal ME, Lipton RB. Modifiable risk factors for migraine progression. Headache46, 1334–1343 (2006).
   PubMed Web of Science ®Google Scholar
• Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache41, 646–657 (2001).
   PubMed Web of Science ®Google Scholar
• Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF; AMPP Advisory Group. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology68, 343–349 (2007).
   PubMed Web of Science ®Google Scholar
• Bigal ME, Lipton RB. Obesity is a risk factor for transformed migraine but not chronic tension-type headache. Neurology67, 252–257 (2006).
   PubMed Web of Science ®Google Scholar
• Bigal ME, Tsang A, Loder E, Serrano D, Reed ML, Lipton RB. Body mass index and episodic headaches: a population-based study. Arch. Intern. Med.167, 1964–1970 (2007).
   PubMedGoogle Scholar
• Winter AC, Berger K, Buring JE, Kurth T. Body mass index, migraine, migraine frequency and migraine features in women. Cephalalgia29, 269–278 (2009).
   PubMedGoogle Scholar
• Rueda-Sánchez M, Díaz-Martínez LA. Prevalence and associated factors for episodic and chronic daily headache in the Colombian population. Cephalalgia28, 216–225 (2008).
   PubMedGoogle Scholar
• Tietjen GE, Herial NA, Hardgrove J, Utley C, White L. Migraine comorbidity constellations. Headache47, 857–865 (2007).
   PubMed Web of Science ®Google Scholar
• Tietjen GE, Peterlin BL, Brandes JL et al. Depression and anxiety: effect on the migraine–obesity relationship. Headache47, 866–875 (2007).
   PubMedGoogle Scholar
• Pompili M, Di Cosimo D, Innamorati M, Lester D, Tatarelli R, Martelletti P. Psychiatric comorbidity in patients with chronic daily headache and migraine: a selective overview including personality traits and suicide risk. J. Headache Pain10, 283–290 (2009).
   PubMed Web of Science ®Google Scholar
• Lipton RB, Bigal ME, Ashina S et al.; American Migraine Prevalence Prevention Advisory group. Cutaneous allodynia in the migraine population. Ann. Neurol.63, 148–158 (2008).
   PubMed Web of Science ®Google Scholar
• Cooke L, Eliasziw M, Becker WJ. Cutaneous allodynia in transformed migraine patients. Headache47, 531–539 (2007).
   PubMed Web of Science ®Google Scholar
• Lovati C, D’Amico D, Rosa S et al. Allodynia in different forms of migraine. Neurol. Sci.28(Suppl. 2), S220–S221 (2007).
   PubMed Web of Science ®Google Scholar
• Ashkenazi A, Sholtzow M, Shaw JW, Burstein R, Young WB. Identifying cutaneous allodynia in chronic migraine using a practical clinical method. Cephalalgia27, 111–117 (2007).
   PubMed Web of Science ®Google Scholar
• Burstein R, Cutrer MF, Yarnitsky D. The development of cutaneous allodynia during a migraine attack clinical evidence for the sequential recruitment of spinal and supraspinal nociceptive neurons in migraine. Brain123, 1703–1709 (2000).
   PubMed Web of Science ®Google Scholar
• Sessle BJ, Hu JW, Amano N, Zhong G. Convergence of cutaneous, tooth pulp, visceral, neck and muscle afferents onto nociceptive and non-nociceptive neurones in trigeminal subnucleus caudalis (medullary dorsal horn) and its implications for referred pain. Pain27, 219–235 (1986).
   PubMed Web of Science ®Google Scholar
• Mainero C, Zhang WT, Kumar A, Rosen BR, Sorensen AG. Mapping the spinal and supraspinal pathways of dynamic mechanical allodynia in the human trigeminal system using cardiac-gated fMRI. Neuroimage35(3), 1201–1210 (2007).
   PubMed Web of Science ®Google Scholar
• Landy S, Rice K, Lobo B. Central sensitisation and cutaneous allodynia in migraine: implications for treatment. CNS Drugs18, 337–342 (2004).
   PubMed Web of Science ®Google Scholar
• Welch KM, Nagesh V, Aurora SK, Gelman N. Periaqueductal gray matter dysfunction in migraine: cause or the burden of illness? Headache41, 629–637 (2001).
   PubMed Web of Science ®Google Scholar
• Ferrari MD, Goadsby PJ, Roon KI, Lipton RB. Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia22, 633–658 (2002).
   PubMed Web of Science ®Google Scholar
• Bigal ME, Borucho S, Serrano D, Lipton RB. The acute treatment of episodic and chronic migraine in the USA. Cephalalgia29, 891–897 (2009).
   PubMed Web of Science ®Google Scholar
• Silberstein SD, Neto W, Schmitt J, Jacobs D; MIGR-001 Study Group. Topiramate in migraine prevention: results of a large controlled trial. Arch. Neurol.61, 490–495 (2004).
   PubMed Web of Science ®Google Scholar
• Silberstein SD, Lipton, RB, Dodick DW et al.Topiramate Chronic Migraine Study Group. Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial. Headache47, 170–180 (2007).
   PubMed Web of Science ®Google Scholar
• Yurekli VA, Akhan G, Kutluhan S, Uzar E, Koyuncuoglu HR, Gultekin F. The effect of sodium valproate on chronic daily headache and its subgroups. J. Headache Pain9, 37–41 (2008).
   PubMed Web of Science ®Google Scholar
• Shuhendler AJ, Lee S, Siu M et al. Efficacy of botulinum toxin type A for the prophylaxis of episodic migraine headaches: a meta-analysis of randomized, double-blind, placebo-controlled trials. Pharmacotherapy29, 784–791 (2009).
   PubMed Web of Science ®Google Scholar
• Freitag FG, Diamond S, Diamond M, Urban G. Botulinum toxin type A in the treatment of chronic migraine without medication overuse. Headache48, 201–209 (2008).
   PubMed Web of Science ®Google Scholar
• Russell MB, Iselius L, Olesen J. Inheritance of migraine investigated by complex segregation analysis. Hum. Genet.96, 726–730 (1995).
   PubMed Web of Science ®Google Scholar
• Stewart WF, Bigal ME, Kolodner K, Dowson A, Liberman JN, Lipton RB. Familial risk of migraine: variation by proband age at onset and headache severity. Neurology66, 344–348 (2006).
   PubMed Web of Science ®Google Scholar
• Stewart WF, Staffa J, Lipton RB, Ottman R. Familial risk of migraine: a population-based study. Ann. Neurol.41, 166–172 (1997).
   PubMed Web of Science ®Google Scholar
• Kruit MC, van Buchem MA, Hofman PA et al. Migraine as a risk factor for subclinical brain lesions. JAMA291, 427–434 (2004).
   PubMed Web of Science ®Google Scholar
• Del Sette M, Dinia L, Bonzano L et al. White matter lesions in migraine and right-to-left shunt: a conventional and diffusion MRI study. Cephalalgia28, 376–382 (2008).
   PubMedGoogle Scholar
• Schmitz N, Admiraal-Behloul F, Arkink EB et al. Attack frequency and disease duration as indicators for brain damage in migraine. Headache48, 1044–1055 (2008).
   PubMedGoogle Scholar
• Kim JH, Suh SI, Seol HY et al. Regional grey matter changes in patients with migraine: a voxel-based morphometry study. Cephalalgia28, 598–604 (2008).
   PubMed Web of Science ®Google Scholar
• Schmidt-Wilcke T, Gänssbauer S, Neuner T, Bogdahn U, May A. Subtle grey matter changes between migraine patients and healthy controls. Cephalalgia28, 1–4 (2008).
   PubMed Web of Science ®Google Scholar
• Aurora SK, Barrodale P, Chronicle EP, Mulleners WM. Cortical inhibition is reduced in chronic and episodic migraine and demonstrates a spectrum of illness. Headache45, 546–552 (2005).
   PubMed Web of Science ®Google Scholar
• Aurora SK, Barrodale PM, Tipton RL, Khodavirdi A. Brainstem dysfunction in chronic migraine as evidenced by neurophysiological and positron emission tomography studies. Headache47, 996–1003 (2007).
   PubMed Web of Science ®Google Scholar